ELISA/assay

Human 1 acyl sn glycerol 3 phosphate acyltransferase beta (AGPAT2) ELISA Kit

MBS756367

48-Strip-Wells

470 USD

ELISA Kit

Human 1 acyl sn glycerol 3 phosphate acyltransferase beta (AGPAT2) ELISA Kit

1 acyl sn glycerol 3 phosphate acyltransferase beta (AGPAT2)

Human 1 acyl sn glycerol 3 phosphate acyltransferase b (AGPAT2) ELISA Kit

1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-AGPAT 2; 1-AGP acyltransferase 2; lysophosphatidic acid acyltransferase beta; lysophosphatidic acid acyltransferase-beta; 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta); 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGP acyltransferase 2; 1-AGPAT 2; Lysophosphatidic acid acyltransferase beta; LPAAT-beta

AGPAT2

AGPAT2

AGPAT2; AGPAT2; BSCL; BSCL1; LPAAB; 1-AGPAT2; LPAAT-beta; 1-AGP acyltransferase 2; 1-AGPAT 2; LPAAT-beta

PLCB_HUMAN

Human

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive

Intended Uses: This ADF ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human ADF. This ELISA kit for research use only, not for therapeutic or diagnostic applications. !Intended Uses: This ADF ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human ADF. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Principle of the Assay: ADF ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-ADF antibody and an ADF-HRP conjugate. The assay sample and buffer are incubated together with ADF-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the ADF concentration since ADF from samples and ADF-HRP conjugate compete for the anti-ADF antibody binding site. Since the number of sites is limited, as more sites are occupied by ADF from the sample, fewer sites are left to bind ADF-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The ADF concentration in each sample is interpolated from this standard curve.

3914362

O15120.1

27,279 Da

Adipogenesis Pathway (198832); CDP-diacylglycerol Biosynthesis I Pathway (142255); CDP-diacylglycerol Biosynthesis I Pathway (138606); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway (160977); Glycerolipid Metabolism Pathway (82986); Glycerolipid Metabolism Pathway (361); Glycerophospholipid Biosynthesis Pathway (645313); Glycerophospholipid Metabolism Pathway (82989)

This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]

AGPAT2: Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Defects in AGPAT2 are the cause of congenital generalized lipodystrophy type 1 (CGL1); also known as Berardinelli-Seip congenital lipodystrophy type 1 (BSCL1) or Berardinelli-Seip syndrome. CGL1 is an autosomal recessive disorder characterized by marked paucity of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Belongs to the 1-acyl-sn-glycerol-3-phosphate acyltransferase family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Transferase; Membrane protein, multi-pass; EC 2.3.1.51; Lipid Metabolism - glycerolipid; Membrane protein, integral; Lipid Metabolism - ether lipid; Lipid Metabolism - glycerophospholipid. Chromosomal Location of Human Ortholog: 9q34.3. Cellular Component: endoplasmic reticulum membrane; endoplasmic reticulum; integral to membrane. Molecular Function: 1-acylglycerol-3-phosphate O-acyltransferase activity. Biological Process: positive regulation of cytokine production; epidermis development; phospholipid metabolic process; glycerophospholipid biosynthetic process; phosphatidic acid biosynthetic process; triacylglycerol biosynthetic process; cellular lipid metabolic process; CDP-diacylglycerol biosynthetic process; positive regulation of cytokine and chemokine mediated signaling pathway. Disease: Lipodystrophy, Congenital Generalized, Type 1

48-Strip-Wells

470 USD

96-Strip-Wells

675